about
A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patientsComparison of hepatocellular carcinoma in Eastern versus Western populations.A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.Capecitabine with radiation is an effective adjuvant therapy in gastric cancers.Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.Targeted therapy in hepatocellular carcinomaThe Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma.National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbiditiesActivity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.Targeted therapies in the treatment of gastric cancer.A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma.Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.Do elderly patients benefit from enrollment into Phase I Trials?Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma."And what other medications are you taking?".Travel warning with capecitabine.Capecitabine-induced oromandibular dystonia: a case report and literature review.Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy.Comparison of health state values derived from patients and individuals from the general population.Hypoglycaemia in a 63-year-old female with a large, recurrent, metastatic gastrointestinal stromal tumour (GIST).Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling.Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.Deconvolution assessment of splenic and splanchnic contributions to portal venous blood flow in liver cirrhosisPrimary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study GroupThe not so innocuous abdominal tapGastrointestinal stromal tumour in the elderlyAn alternative therapy for patients with hepatic impairment?Variable problems in lymphomas: CASE 1. Burkitt's lymphoma presenting with central airway obstructionExpression of heparan sulfate in gastric carcinoma and its correlation with clinicopathological features and patient survivalPhase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancerFirst-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
P50
Q26771580-F47F1FC9-AB03-48AA-86DD-ED5F4FBEB029Q28544740-A146D20E-38F4-4F61-9CD8-3D20EAE1E622Q30245396-79907CBA-2033-442B-BDCC-BBF197A59CCFQ33404971-22AD176C-E189-4F6E-9B61-DBCE6AB6CB63Q34041435-657289CE-20C9-419C-80B5-57A652065512Q34851700-37BE85E2-EB5B-4579-9FCF-E04715F152D7Q35116226-33240D47-F161-43AA-9D17-7BAE0B721C5EQ35207561-9C669573-62EA-4414-BDEC-20FB2E607CEAQ35241955-6B2A54DC-5056-4F36-B7C9-1F026F5C8088Q37000692-643DCF90-DDCF-4D2B-A6C2-AE1DC371DA99Q37072527-D00D2744-CFCD-4AC1-9E2E-6412262B978DQ37641056-57FBFDB7-413E-4FBC-BD5B-43A2DC7E5003Q37850250-3356EC70-66A6-4488-95B5-BCEBD9AA8207Q37925131-96939798-B118-433F-A758-3E7B8AFD03CFQ38608611-0F976E24-B06B-49AC-8EFC-DC5B139C83ADQ39452813-CAFC5AC8-3BD5-4CCE-8F19-8D06D92F0DE1Q39491717-E4536C4B-7AF0-429C-AFDF-9DA0A5C89B7FQ39775573-1F54CCF1-403C-4019-B524-AC29EAC8925AQ39799639-36413F5E-5788-45E9-AFD0-DF4A0280679CQ40705749-3DE77255-A5D5-4DCC-95FD-DEA211F0E6E3Q40802449-F3BCC99D-D9DA-4171-A378-6164F77A2EE0Q41206262-EA471B90-664B-472D-95AE-2C09F7D197D2Q42556974-5C386E74-256D-40A7-B289-D3028026F4FCQ45961096-7E1B92E3-1745-4917-B6C5-F6DBFD56A353Q45995961-9BFC9787-CD53-4F12-A0B2-6C1A558D8696Q46496664-340559B3-D5E7-480B-9EA3-E0F7FB33E155Q46973510-FDB78E52-77DE-46F8-A4BE-DF05979B383AQ48238595-02BD6C9C-C9A2-40A2-B59E-1972B45C6BD8Q51533762-4CEC976F-379C-4828-BA9A-698EC700744EQ53375330-B23E7265-150B-4357-BA5D-74C42BE18609Q53458025-38F74EA6-4CD8-459C-B826-B6F6D513847FQ57551298-7229510B-AAAA-450C-971C-C9787C61DA41Q57903247-CF8D58BD-1D00-4C46-AA92-14C561962696Q79434193-C160BCBC-F70B-4241-8825-AA2EB825DE04Q79769833-A22FBC94-A178-45DE-8D17-71E854E943F4Q81342874-FF8C2417-0FB9-454E-AF33-F5A2320F3086Q81419177-02497DCF-FBCB-4CB5-A185-155C594EC327Q82949635-C8C7E4CC-0760-4F18-AC86-8FAB5A1040E6Q84252425-CBC9D489-1AA7-44EE-95BA-C06912670ED8Q90423285-027BF3A8-5056-486B-A8D0-86776063DF06
P50
description
investigador
@es
researcher
@en
name
Su-Pin Choo
@en
Su-Pin Choo
@nl
type
label
Su-Pin Choo
@en
Su-Pin Choo
@nl
prefLabel
Su-Pin Choo
@en
Su-Pin Choo
@nl
P31
P496
0000-0002-8925-3922